Drug Trial Radar · NCT02281682
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Oct 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
624
Actual
Start
Nov 2014
Primary completion
Jul 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Maastricht University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-centre randomised controled single blind clinical phase IV trial with the aim to determine the most effective treatment in terms of lesion reduction, costs and patient satisfaction in treatment of actinic keratosis (AK), when comparing topical treatment with photodynamic therapy (PDT), 5% 5-fluorouracil (5-FU) cream, 5% Imiquimod (IMI) cream and ingenol mebutate (IM) gel.
Conditions
- Keratosis, Actinic
Interventions
ImiquimodDrug
three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
5-fluorouracilDrug
during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
Ingenol mebutateDrug
during 3 (consecutive) days once daily. Prior to treatment: curettage
methylaminolevulinate photodynamic therapyProcedure
methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
Primary outcomes
What the sponsor says the trial is designed to measure.
- treatment succesTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maastricht UMC
Maastricht, Limburg, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.